Group 1 - The core viewpoint of the report is that Anke Bio (300009.SZ) is rated as a buy due to its continuous development in main business and overall stable performance of the parent company [2] - The company is actively expanding new business areas to create growth points for its performance [2] - Anke Bio is focusing on cutting-edge technologies, with accelerated innovation and research and development efforts [2]

Core Viewpoint - Anke Biological experienced a stock price decline of 2.07% on August 22, with a current price of 11.38 yuan per share and a total market capitalization of 19.033 billion yuan [1] Company Overview - Anhui Anke Biological Engineering (Group) Co., Ltd. was established on September 28, 2000, and listed on October 30, 2009. The company specializes in research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1] - The main revenue composition includes 88.24% from gene engineering drugs, 11.67% from external patches, and 0.09% from other sources [1] Financial Performance - For the first half of 2025, Anke Biological reported operating revenue of 1.292 billion yuan, a year-on-year decrease of 0.51%, and a net profit attributable to shareholders of 367 million yuan, down 11.92% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 2.662 billion yuan, with 1.252 billion yuan distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders is 65,700, a decrease of 2.17% from the previous period, with an average of 18,598 circulating shares per person, an increase of 2.22% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, holding 20.7916 million shares, an increase of 7.341 million shares from the previous period [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][11]. Core Insights - The company reported a revenue of 1.292 billion RMB for the first half of 2025, a slight decrease of 0.51% year-on-year, with a net profit attributable to shareholders of 367 million RMB, down 11.92% year-on-year [2]. - The company's main business, particularly its biological products, has shown resilience with a 5.13% year-on-year increase in revenue for the parent company, despite a decline in net profit [3]. - The company is actively expanding its business through strategic partnerships and new product rights, which are expected to enhance its growth trajectory [3]. - The company is advancing its innovative research and development efforts, with several clinical trials underway for new therapies, including CAR-T cell drugs and mRNA vaccines [4]. Financial Performance - The company expects to achieve net profits of 794 million RMB, 904 million RMB, and 1.011 billion RMB for the years 2025, 2026, and 2027, respectively, reflecting growth rates of 12%, 14%, and 23% [5]. - The earnings per share (EPS) for the years 2025, 2026, and 2027 are projected to be 0.48 RMB, 0.54 RMB, and 0.60 RMB, with corresponding price-to-earnings (P/E) ratios of 24, 22, and 19 [5]. Market Position - The company has successfully reversed the declining trend in its main biological products, with a notable 298% increase in sales of its injection product, "Anshaiting" [3]. - The report highlights the company's strategic collaborations, including exclusive commercialization rights for a new product and a partnership for a growth hormone product, which are expected to strengthen its market position [3].

Group 1 - Anke Bio (300009.SZ) released its semi-annual report for 2025 on August 22, 2025, showing that as of August 21, 2025, 12 institutional investors held a total of 81.64 million shares, accounting for 4.88% of the total share capital [1] - The top ten institutional investors include Hong Kong Central Clearing Limited, Bank of China - CMB National Bio-Medicine Index Fund, Shanghai Bank - Yinhua CSI Innovative Drug Industry ETF, and others, with a combined holding ratio of 4.88%, which decreased by 0.62 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, three funds reduced their holdings compared to the previous quarter, including the Innovative Drug Fund and CMB National Bio-Medicine Index A, with a reduction ratio of 0.31% [2] - Seven new public funds were disclosed this period, including Southern CSI 1000 ETF and various funds from Fortune, while two funds were no longer disclosed compared to the previous quarter [2] - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.44% compared to the previous period [2]

Core Viewpoint - The company has shown resilience in its business performance, with a notable increase in revenue from its main biological products, particularly a significant growth in sales of its flagship product, trastuzumab injection "Ansaiting" [5][6]. Company Overview - The company did not distribute cash dividends or issue bonus shares during the reporting period [3]. - There were no changes in the controlling shareholder or actual controller during the reporting period [5]. Financial Performance - The company's main business in biological products reversed the previous year's decline, achieving a year-on-year revenue growth of 7.49% [5]. - Sales revenue of trastuzumab injection "Ansaiting" increased by 298% year-on-year [5]. Business Development - The company secured exclusive commercialization rights for a new long-acting follicle-stimulating hormone product, enhancing its product portfolio in the assisted reproduction field [6]. - Strategic cooperation with Weisheng Pharmaceutical aims to cover all dosage forms of growth hormone products, strengthening the company's market position in pediatric growth development [6]. Production and Quality Management - The company is constructing a new production base covering pharmaceutical R&D, intelligent production, and sales, with approximately 90,000 square meters of infrastructure completed [7]. - New production lines for growth hormone injection and trastuzumab injection have received production licenses and are in the registration and review stages [8]. Research and Development - The company is advancing several clinical trials, including the HuA21 project and AK2017 injection, with plans for further phases of clinical research [8][9]. - The company has received approval for the launch of its acetate atogepant injection, expanding its product offerings in peptide formulations [9]. Innovative Technologies - The company is developing a CAR-T cell therapy and a recombinant adenovirus injection for cancer treatment, with clinical trials progressing [10]. - Collaborations with other companies are ongoing to enhance the development of innovative ADC drugs, expanding the company's pipeline in precision oncology [10].

Core Viewpoint - Anke Biological reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.292 billion yuan, a year-on-year decrease of 0.51% [2] - The net profit attributable to shareholders was around 367 million yuan, reflecting a year-on-year decline of 11.92% [2] - Basic earnings per share were 0.2191 yuan, down 11.72% compared to the previous year [2]

Core Viewpoint - Anke Biotech announced the resignation of supervisor Li Chenghua due to personal reasons, effective immediately, and she will not hold any other positions within the company [2]. Financial Performance - For the first half of 2025, Anke Biotech's revenue composition is as follows: Gene engineering drugs account for 73.51%, other businesses account for 16.77%, and external patches account for 9.72% [2].

格隆汇8月21日丨安科生物(300009.SZ)公布半年度报告，报告期内，公司实现营业收入129,218.79万 元，同比下降0.51%，其中母公司实现营业收入91,031.22万元，同比增长5.13%；实现归属于上市公司 股东的净利润36,651.72万元，同比下降11.92%。 ...

Group 1 - The company held the 19th meeting of the 8th Supervisory Board on August 20, 2025, with all three attending supervisors voting unanimously to approve the half-year report and its summary [1][2] - The Supervisory Board confirmed that the procedures for preparing and reviewing the half-year report complied with legal and regulatory requirements, and the report accurately reflects the company's operational status without any false statements or omissions [1][2] Group 2 - The Supervisory Board approved a proposal to repurchase and cancel certain restricted stocks that do not meet incentive conditions from the third phase of the stock incentive plan [2] - The repurchase and cancellation will not affect the continuation of the third phase of the incentive plan, which will proceed according to regulatory requirements [2]

安徽天禾律师事务所 法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 第三期限制性股票激励计划 回购注销部分限制性股票相关事项 之 法律意见书 致：安徽安科生物工程（集团）股份有限公司 安徽天禾律师事务所（以下简称"本所"）接受安徽安科生物工程（集团） 股份有限公司（以下简称"安科生物"或"公司"）的委托，担任安科生物实 施第三期限制性股票激励计划相关事宜（以下简称"本次股权激励计划"或"激 励计划"）的专项法律顾问。本所律师根据《中华人民共和国公司法》（以下 简称《公司法》）《上市公司股权激励管理办法》（证监会 148 号令）（以下 简称《管理办法》）《深圳证券交易所创业板股票上市规则》（以下简称《上 市规则》）《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》等有关法律及其他有关法律、法规、规范性文件，以及《安徽安科生物工 程（集团）股份有限公司第三期限制性股票激励计划（草案）》（以下简称《激 励计划》）和《安徽安科生物工程（集团）股份有限公司公司章程》（以下简 称《公司章程》）的相关规定，对本次股权激励计划所涉及的回购注销部分限 制性股票相关事项出具本法律意见 ...